View topic-related background literature as well as publications of the DECISION consortium itself. As soon as new publications are available, we list them here. All publications of DECISION will be open access for everyone, linked directly to the full-text version of the respective journal, publisher, or online repository. For PDFs of our own press releases please go to DOWNLOADS. To receive our newsletter, please subscribe here!
DECISION Publications (count: 0)
2021
Coming soon
Publications by DECISION partners
- Bischoff J et al. (2021). Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine. 40: 101116
- Chang J et al. (2021). Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal Models. Front Physiol. 12: 720898
- Claria J et al. (2021). Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis. J Hepatol. 75 (5): pp. 1116-1127
- Claria J et al. (2021). Proresolving lipid mediators and liver disease. BBA Mol & Cell Biol Lipids. 1866 (11): 159023
- Duran-Güell M et al. (2021). Albumin protects the liver from tumor necrosis factor α-induced immunopathology. The FASEB Journal. 35 (2): e21365
- Engelmann C et al. (2021). Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 75 (1): pp. 49-66
- Iwakiri Y and Trebicka J (2021). Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP. 3 (4): 100316
- Lin T et al. (2021). Follistatin-controlled activin-HNF4α-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure. Hepatology. Online ahead of print.
- Sauerbruch T et al. (2021). Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol. 12: 718783
- Casulleras M et al. (2020). Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. Sci Transl Med. 12 (566)
- Casulleras M et al. (2020). Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells. 9 (12): 2632
- De Lecuona, I (2020). Guidelines for reviewing health research and innovation that use emergent technologies and personal data. Edicions de la Universitat de Barcelona. 978-84-9168-646-0
Background Reading
- Trebicka J, Fernandez J, Papp M et al. (2020). PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol. ePub ahead of print
- Trebicka J, Fernandez J, Papp M et al. (2020). The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology. J Hepatol. ePub ahead of print
- Claria J et al. (2019). Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. Hepatology. 69 (4): pp. 1686-1701
- Allen AM and Kim WR (2016). Epidemiology and Healthcare Burden of Acute-on-Chronic Liver Failure. Semin Liver Dis. 36 (2): pp. 123-126
- Arroyo V et al. (2016). Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers. 2, Article number: 16041
- Ge PS and Runyon BA (2016). Treatment of Patients with Cirrhosis. N Engl J Med. 375 (8): pp. 767-777
- Moreau R et al. (2013). Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 144 (7): pp. 1426-1437